Cumulative incidence of prostate cancer diagnosis by risk category for a simulated follow-up of 2,000,000 men from age 40 to age 100 under three different levels of diagnostic activity: Low as in Sweden 1992; Intermediate as in Sweden 2016; High as in Stockholm 2014; when the Stockholm-3 study invited men to measure their PSA [15].</p
Objective To assess the strength of the evidence indicative of prostate cancer (PCa) progression as ...
Aim: Although prostate-specific antigen (PSA) screening reduces mortality from prostate cancer, subs...
Background: To describe the variation in PSA level by age group and screening round in the ERSPC cen...
Cumulative incidence of prostate cancer diagnosis by risk category for a simulated follow-up of 2,00...
Lifetime risk of low to intermediate-risk prostate cancer diagnosis (in blue), and high risk or meta...
IMPORTANCE: The diagnostic activity for prostate cancer has increased during the past decades. Howev...
The main aim of the study was to determine the impact of diagnostic activity and life expectancy on ...
Objective. To investigate the effects of prostate-specific antigen (PSA) testing of men without clin...
BackgroundOptimal prostate cancer (PCa) screening strategies will focus on men likely to have potent...
Since the late 90’s the diagnostic activity for prostate cancer has increased in Sweden, primarily d...
The diagnostic activity for prostate cancer has increased substantially in Sweden, primarily due to ...
The effect of prostate-specific antigen (PSA) screening on prostate cancer mortality remains debated...
IMPORTANCE: The long-term outcomes among men with prostate cancer (PC) whose disease is managed with...
Age-standardised prostate cancer incidence rates from the simulation model compared with those obser...
Prostate cancer is a large and increasing medical problem both in Sweden and in the rest of the deve...
Objective To assess the strength of the evidence indicative of prostate cancer (PCa) progression as ...
Aim: Although prostate-specific antigen (PSA) screening reduces mortality from prostate cancer, subs...
Background: To describe the variation in PSA level by age group and screening round in the ERSPC cen...
Cumulative incidence of prostate cancer diagnosis by risk category for a simulated follow-up of 2,00...
Lifetime risk of low to intermediate-risk prostate cancer diagnosis (in blue), and high risk or meta...
IMPORTANCE: The diagnostic activity for prostate cancer has increased during the past decades. Howev...
The main aim of the study was to determine the impact of diagnostic activity and life expectancy on ...
Objective. To investigate the effects of prostate-specific antigen (PSA) testing of men without clin...
BackgroundOptimal prostate cancer (PCa) screening strategies will focus on men likely to have potent...
Since the late 90’s the diagnostic activity for prostate cancer has increased in Sweden, primarily d...
The diagnostic activity for prostate cancer has increased substantially in Sweden, primarily due to ...
The effect of prostate-specific antigen (PSA) screening on prostate cancer mortality remains debated...
IMPORTANCE: The long-term outcomes among men with prostate cancer (PC) whose disease is managed with...
Age-standardised prostate cancer incidence rates from the simulation model compared with those obser...
Prostate cancer is a large and increasing medical problem both in Sweden and in the rest of the deve...
Objective To assess the strength of the evidence indicative of prostate cancer (PCa) progression as ...
Aim: Although prostate-specific antigen (PSA) screening reduces mortality from prostate cancer, subs...
Background: To describe the variation in PSA level by age group and screening round in the ERSPC cen...